Vanda Pharmaceuticals, Inc.

  • Sleep War Z: A Written History of the Insomniac War

    By Leo Sun - July 31, 2013 | Tickers: MRK, SNY, VNDA

    It’s estimated that 30% to 40% of adults in the world experience some degree of insomnia every year. Most of these cases aren’t chronic and do not require medication. However, 10% to 15% of American adults reportedly suffer from chronic insomnia, which lasts for months at a time. Anxiety and depression are frequent causes of chronic insomnia, and currently available insomnia medications often contain some similar ingredients as more »

  • Assessing Raptor Pharmaceutical's Agreement With HealthCare Royalty Partners

    By Alexander Maxwell - June 14, 2013 | Tickers: CORT, RPTP, VNDA

    Raptor Pharmaceuticals (NASDAQ: RPTP) signed an agreement with HealthCare Royalty Partners. On the face, this deal looks good for shareholders injecting much needed capital into the company. However, this agreement might not in reality be as good as it initially appeared for shareholders. 

    Some specifics of the agreement point out red flags for shareholders. One specific red flag for shareholders is the interest rate on the loan. 

    "Under the terms more »

  • Four Companies That Stuck Out on Tuesday; and that Might Trade Higher

    By Brian Nichols - December 19, 2012 | Tickers: ARB, TROX, VNDA, YOKU

    On a day when almost all stocks performed well, there were a few that shined above the rest. And in this article, I am looking at the best of the best, I am determining what moved the stocks, and lastly whether or not the catalyst could lead to additional gains.

    Company

    Ticker

    Gains

    Arbitron

    (NYSE: ARB)

    23.63%

    Yoku

    (NYSE: YOKU)

    13.51%

    Tronox

    (NYSE: TROX)

    9.84%

  • 8 Healthcare Stocks For Your 2012 Watchlists (Part 2)

    By Michael French - January 16, 2012 | Tickers: MDT, VNDA, ZMH

    This is a continuation from Part 1.

    Medtronic, Inc. (NYSE: MDT) – In addition to offering a dividend yield of 2.5%, MDT has strong fundamental metrics relative to its peers. Most comparable to MDT are Boston Scientific (BSX) and Johnson & Johnson (JNJ). On a valuation basis, MDT is currently trading at a price-to-earnings multiple of 12.2, relative to 14.6 for BSX and 15.9 for JNJ. On an more »